07:17 AM EST, 01/03/2025 (MT Newswires) -- GSK (GSK) said Friday that the China National Medical Products Administration has approved Nucala, or mepolizumab, as an add-on therapy with intranasal corticosteroids to treat adult patients with inadequately controlled chronic rhinosinusitis with nasal polyps.

The company said the approval was based on the results of a phase 3 trial of mepolizumab in a population of Japanese, Chinese and Russian patients that achieved the co-primary endpoints of changes from baseline in nasal obstruction visual analogue scale score and endoscopic nasal polyp score.

The new approval marks the third indication for mepolizumab in China, GSK said.